Recombinant antibody production has emerged as a potent and ground-breaking technology in biomedical research. It has completely transformed the way scientists and researchers study illnesses, create ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...
The second RZV dose increased immunity against herpes zoster virus outcomes when administered within an extended window after the first dose.
A target trial emulation was conducted to assess the effectiveness of recombinant zoster vaccine (RZV) accounting for prior ...
CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3GEleva successfully completed ...
Recombinant quadrivalent influenza vaccine (RIV4) and standard egg-based quadrivalent inactivated IV (IIV4) show comparable effectiveness in reducing influenza-related hospitalization among older ...
Two doses of the recombinant herpes zoster (HZ; shingles) vaccine (RZV) are effective even for people who previously received ...
EMA committee issues positive opinion to support the approval of GSK’s recombinant zoster vaccine, Shingrix in a prefilled syringe: London, UK Wednesday, October 22, 2025, 16:00 ...
ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, today announced the launch of its latest product: CHO cell–derived recombinant ...
New 2025 dataset shows Cell Signaling Technology, Thermo Fisher Scientific and Abcam lead the antibody market despite challengers, as well as the continued impact of recombinant and secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback